LanZhou Foci Pharmaceutical Co.,Ltd. (SHE:002644)
8.72
-0.20 (-2.24%)
Apr 9, 2026, 3:04 PM CST
SHE:002644 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Equivalents | 524.49 | 397.89 | 406.04 | 397.85 | 374.94 |
Trading Asset Securities | - | - | - | 2 | - |
Cash & Short-Term Investments | 524.49 | 397.89 | 406.04 | 399.85 | 374.94 |
Cash Growth | 31.82% | -2.01% | 1.55% | 6.64% | -17.06% |
Accounts Receivable | 474.08 | 413.57 | 382.65 | 435.88 | 344.8 |
Other Receivables | 3.28 | 45.59 | 50.5 | 62.98 | 12.34 |
Receivables | 477.36 | 459.17 | 433.15 | 498.87 | 357.14 |
Inventory | 289.84 | 339.99 | 369.72 | 363.26 | 258.83 |
Prepaid Expenses | - | 0.04 | 0.9 | - | - |
Other Current Assets | 41.05 | 24.79 | 29.06 | 42 | 43.72 |
Total Current Assets | 1,333 | 1,222 | 1,239 | 1,304 | 1,035 |
Property, Plant & Equipment | 986.96 | 1,032 | 1,062 | 1,068 | 1,092 |
Long-Term Investments | 69.93 | 55.66 | 64.1 | 68.67 | 71.65 |
Goodwill | 9.01 | 9.01 | 9.01 | 9.01 | 4.47 |
Other Intangible Assets | 73.55 | 76.87 | 79.55 | 76.79 | 71.96 |
Long-Term Deferred Tax Assets | 65.79 | 61.81 | 53.65 | 53.98 | 51.11 |
Long-Term Deferred Charges | 1.84 | 3.76 | 7.65 | 6 | 0.89 |
Other Long-Term Assets | 7.66 | 8.78 | 13.43 | 20.41 | 25.76 |
Total Assets | 2,547 | 2,470 | 2,528 | 2,606 | 2,352 |
Accounts Payable | 263.63 | 213.09 | 310.37 | 314.47 | 214.3 |
Accrued Expenses | 1.78 | 10.21 | 11.46 | 28.86 | 9.9 |
Short-Term Debt | 21.7 | 10 | 10 | - | - |
Current Portion of Long-Term Debt | 16.09 | 13.92 | 13.89 | 13.4 | 14.2 |
Current Portion of Leases | - | 0.82 | 0.8 | 0.87 | 0.5 |
Current Income Taxes Payable | 26.27 | 19.08 | 27.42 | 44.74 | 44.26 |
Current Unearned Revenue | 50.75 | 16.05 | 47.02 | 99.93 | 35.91 |
Other Current Liabilities | 60.41 | 96.56 | 46.74 | 40.28 | 55.78 |
Total Current Liabilities | 440.62 | 379.73 | 467.69 | 542.54 | 374.84 |
Long-Term Debt | 6.2 | 15 | 26.6 | 40.37 | 53.14 |
Long-Term Leases | 1.51 | 1.05 | 1.35 | 0.97 | 0.81 |
Long-Term Unearned Revenue | 241.4 | 256.1 | 260.96 | 278.15 | 294.96 |
Long-Term Deferred Tax Liabilities | 2.3 | 2.93 | 3.07 | 3.18 | 0.85 |
Total Liabilities | 692.03 | 654.81 | 759.67 | 865.21 | 724.59 |
Common Stock | 510.66 | 510.66 | 510.66 | 510.66 | 510.66 |
Additional Paid-In Capital | 337.39 | 337.39 | 337.38 | 352.33 | 343.51 |
Retained Earnings | 983.95 | 940.88 | 896.13 | 854.47 | 758.78 |
Comprehensive Income & Other | 0.66 | 0.96 | 1.21 | 1.6 | 1.62 |
Total Common Equity | 1,833 | 1,790 | 1,745 | 1,719 | 1,615 |
Minority Interest | 22.79 | 25.09 | 23.06 | 22.17 | 12.92 |
Shareholders' Equity | 1,855 | 1,815 | 1,768 | 1,741 | 1,628 |
Total Liabilities & Equity | 2,547 | 2,470 | 2,528 | 2,606 | 2,352 |
Total Debt | 45.49 | 40.79 | 52.63 | 55.6 | 68.65 |
Net Cash (Debt) | 479 | 357.1 | 353.41 | 344.26 | 306.29 |
Net Cash Growth | 34.13% | 1.04% | 2.66% | 12.39% | -12.86% |
Net Cash Per Share | 0.94 | 0.70 | 0.69 | 0.67 | 0.60 |
Filing Date Shares Outstanding | 510.33 | 510.66 | 510.66 | 510.66 | 510.66 |
Total Common Shares Outstanding | 510.33 | 510.66 | 510.66 | 510.66 | 510.66 |
Working Capital | 892.12 | 842.16 | 771.18 | 761.43 | 659.79 |
Book Value Per Share | 3.59 | 3.51 | 3.42 | 3.37 | 3.16 |
Tangible Book Value | 1,750 | 1,704 | 1,657 | 1,633 | 1,538 |
Tangible Book Value Per Share | 3.43 | 3.34 | 3.24 | 3.20 | 3.01 |
Buildings | - | 945.9 | 938.67 | 933.74 | 927.81 |
Machinery | - | 377.02 | 366.31 | 333.01 | 317.82 |
Construction In Progress | - | 1.76 | 3.3 | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.